Contineum Therapeutics, Inc. (CTNM) vs REGENXBIO Inc. (RGNX)
Contineum Therapeutics, Inc. and REGENXBIO Inc. are both Biotechnology companies. Contineum Therapeutics, Inc. and REGENXBIO Inc. are of similar size ($487.8M and $469.9M). Contineum Therapeutics, Inc. has the higher net margin (0.00% vs −112.6%) and the lower return on invested capital (−1,334.4% vs 0.00%). Across the 12 metrics below, Contineum Therapeutics, Inc. leads on 9 and REGENXBIO Inc. on 3.
Valuation
Profitability
| Metric | CTNM | RGNX | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 86.38% | 65.16% |
| Operating margin | 0.00% | (94.08%) | 0.00% |
| Net margin | 0.00% | (112.58%) | 0.00% |
| Free cash flow margin | 0.00% | (143.09%) | 0.00% |
| Return on equity | (28.01%) | (137.63%) | (57.72%) |
| Return on assets | (26.57%) | (40.60%) | (49.22%) |
| Return on invested capital | (1,334.41%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack